Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.

Medicare covers Wegovy as a treatment to reduce the risk of serious cardiovascular events in people who have overweight or obesity. It does not cover Wegovy for weight loss.

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

As the leaves start to turn and the air gets a little crisper, it’s also time to make some important healthcare ...

The Centers for Medicare and Medicaid Services (CMS) just shared a preliminary list of generic drugs it plans to make ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years ...

Millions of older Americans with obesity could potentially get Medicare's help with the hefty price of a weight-loss medication in order to reduce their high risk of heart problems. But exactly ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...